ClinicalTrials.gg
TerminatedNCT04856787Updated May 18, 2025

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

A Phase 2/3 interventional study of SHR-1701、 BP102 、XELOX and SHR-1701、 BP102 、XELOX in Metastatic Colorectal Cancer (mCRC), sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Adjustment of the Company's R\&D Strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 2 open to participants now, 5 under way, 3 of them phase 3. Colorectal Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 11
62 · median 103
Started
2021
with 1 other
Phase 2/3
2 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2/3, and was the 6th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Colorectal Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.

03

Conditions studied

  • Metastatic Colorectal Cancer (mCRC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unresectable recurrent or adenocarcinoma of the colon or rectum confirmed histologically
  2. For subjects who have not previously received any systemic antitumor therapy and who have previously received or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
  3. At least 1 according to V1.1
  4. The vital organs are functioning well
  5. score is 0 \~ 1
  6. was initiated from the signing of the until at least 6 months after the last dosing of the study drug

Exclusion criteria

Exclusion Criteria:

  1. Recurrent or lesions can be treated with radical surgery
  2. Presence of central nervous system or meningeal metastases;
  3. Moderate and severe ascites of clinical symptoms;Uncontrolled or moderate or greater pleural effusion or pericardial effusion
  4. Poorly controlled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the case of regular antihypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy
  5. Severe cardiovascular and cerebrovascular diseases;Have clinical heart symptoms or diseases that are not well controlledSubjects with a history of myocardial infarction or unstable angina pectoris
  6. Subject with current interstitial pneumonia or interstitial lung disease, or with a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy
  7. Previous treatment with targeted T cell costimulatory molecules and ;Previous treatment with antiepidermal growth factor receptor or any antiangiogenic drug
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    SHR-1701 in combination with BP102 and XELOX(Phase 2)

    Drug: SHR-1701、 BP102 、XELOX

  • Experimental
    SHR-1701 in combination with BP102 and XELOX (Phase 3)

    Drug: SHR-1701、 BP102 、XELOX

  • Placebo comparator
    placebo in combination with BP102 and XELOX

    Drug: placebo、 BP102、 XELOX

Interventions

  • Phase 2:Single Group Drug:SHR-1701 30mg/kg,IV ,every 3 week Drug:BP102 7.5mg/kg,IV,every 3 week Drug: Oxaliplatin 130mg/m2 ,IV,every 3 week Drug:Capecitabine The total daily dose was 2000mg/m2, OR,Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

  • Phase 3:Randomized Drug:SHR-1701 30mg/kg,IV ,every 3 week Drug:BP102 7.5mg/kg,IV,every 3 week Drug: Oxaliplatin 130mg/m2 ,IV,every 3 week Drug:Capecitabine The total daily dose was 2000mg/m2, OR,Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

  • Drugplacebo、 BP102、 XELOX

    Phase 3:Randomized Drug:Placebo 30mg/kg,IV ,every 3 week Drug:BP102 7.5mg/kg,IV,every 3 week Drug: Oxaliplatin 130mg/m2 ,IV,every 3 week Drug:Capecitabine The total daily dose was 2000mg/m2, OR,Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

06

What researchers measure

Primary outcomes

  1. Phase 2:ORR

    Objective response rate (assessed by the investigators based on RECIST v1.1)

    Time frame: up to 2 years

  2. Phase 2:Incidence of Adverse Events (AEs) by CTCAE v5.0

    Assess safety and tolerability of SHR-1701 in combination with BP102 and XELOX

    Time frame: up to 2 years

  3. Phase 3:PFS

    Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

Secondary outcomes

  1. DCR

    Disease control rate,the proportion of patients with the best overall response of CR, PR, or stable disease (SD) 。

    Time frame: up to 2 years

  2. OS

    Overall survival ,from the date of first dose unitl the date of death from any cause。

    Time frame: up to 2 years

  3. PFS

    Progression-free survival from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed (assessed by independent radiological review committee (IRRC) based on iRECIST,by the investigators based on RECIST v1.1))。

    Time frame: up to 2 years

  4. Duration of response

    Duration of response,from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed

    Time frame: up to 2 years

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Apr 2024, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Apr 23, 2021
StartActual
Jun 22, 2021
Primary completionActual
Apr 17, 2024
CompletionActual
Apr 17, 2024
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04856787
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
Jun 22, 2021
Primary completion
Apr 17, 2024
Completion
Apr 17, 2024
Last update
May 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BP102

Start the discussion